Bayer Enters CAR-T Space With Atara Pact
Pays $60m Upfront
Executive Summary
Marianne De Backer, head of pharma BD and licensing at the German firm, told Scrip, "We strongly believe that the future is allogeneic and we were looking for pioneers in the field."